GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ? an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE Healthcare will provide a supply of Optison to the U.S. and European markets from its manufacturing facility in Oslo, Norway, becoming the only contrast media manufacturer to supply its own stock to the United States.
The U.S. Food and Drug Administration (FDA) is warning healthcare professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents Lexiscan (regadenoson) and Adenoscan (adenosine).
Exponential growth in vendor neutral archive (VNA) study volumes is forecast to drive strong demand for VNA solutions in the next five years, according to a report titled “Medical Enterprise Data Storage — World — 2013” from IHS, a global source of critical information and insight.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Data from a national registry developed to track patient safety and real-world outcomes finds that the initial use of transcatheter aortic valve replacement (TAVR) for treatment of aortic stenosis in high surgical risk and inoperable patients in the United States is safe and effective.
AliveCor Inc. launched a mobile heart health service, offering expert reviews of electrocardiograms (ECGs) recorded through their smartphone application.
One of the biggest complaints patients have with MR imaging is the loud acoustic noise. The sound produced by the powerful gradients makes patients uncomfortable. This discomfort results in longer exams and sometimes poor image quality because patients can’t stay still. Toshiba America Medical Systems, Inc. is helping clinicians improve the MR experience with its Pianissimo technology.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The RSNA FastPass is produced by Imaging Technology News (ITN) as a guide to what vendors are highlighting. It helps attendees better navigate the vast technical exhibit floor to find what they are looking for.
Cephasonics introduced the small, 2-pound cQuest Dragonfly family of modular 32- or 64-channel, high-performance ultrasound systems, which, along with the included cQLink network communications technology, it will showcase at Medica 2013 Nov. 20-23 in Dusseldorf, Germany.
Eizo Inc. announced the release of the RadiForce RX650, a 30-inch color LCD monitor ideal for multi-modality applications.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
A multidisciplinary team of experts in heart failure, cardiac arrhythmia and neurosurgery at Mount Sinai Hospital in New York City are testing nerve stimulation in the neck as a therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath and heart arrhythmias while reducing their hospitalizations.
The 2014 Top 10 Health Technology Hazards list raises awareness of the potential dangers associated with the use of medical devices and helps healthcare providers minimize the risk of technology-related adverse events.
Video game technology is being applied to imaging by German researchers, who will be presenting their findings at RSNA 2013. Xbox in the operating room and the use of video game controllers in visualizing organs and tumors, an ultra-sensitive MRI technology for early detection of cancer and a one-stop stroke management technology are among advances coming from scientists affiliated with the German Federal Ministry for Education and Research (BMBF):
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Neovasc Inc. reported the results from its COSIRA (coronary sinus reducer for treatment of refractory angina) trial assessing the efficacy and safety of the Neovasc Reducer, a percutaneous device for the treatment of refractory angina.
Esaote will showcase Prevention Suite, a unique package of ultrasound imaging modalities for both cardiac and vascular investigations at the EuroEcho-Imaging 2013 conference Dec. 11-14 in Istanbul, Turkey.
The use of renal stenting in combination with medication-based therapy to treat hypertension showed no improvement in patient outcomes over the use of medications alone in treating hypertension. The results from the highly-anticipated CORAL trial were presented at the American Heart Assn. (AHA) 2013 Scientific Sessions in Dallas.